Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 5/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17306126 | 0.84 | SLC18A3 (0.49) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL29964208 | 0.83 | SLC18A3 (0.57) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL16994792 | 0.83 | SLC18A3 (0.51) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL4519074 | 0.81 | SLC18A3 (0.52) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL520947 | 0.81 | SLC18A3 (0.52) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL520946 | 0.81 | SLC18A3 (0.52) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL9952448 | 0.80 | KMT2A (0.52) | SLC18A3TLR8TLR7TLR9 | |
| SCHEMBL520726 | 0.80 | SLC18A3 (0.55) | SLC18A3TLR8TLR7TLR9 | |
| SCHEMBL520725 | 0.80 | SLC18A3 (0.55) | SLC18A3TLR8TLR7TLR9 | |
| SCHEMBL4403445 | 0.80 | SLC18A3 (0.48) | SLC18A3TLR8TLR7TLR9DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3517536-B1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3517536-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180370955-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2018-12-27 | — | — | US | disclosed |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-3197884-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| WO-2016049211-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370955-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | SLC18A3 4614/4885TLR8 3481/4885TLR7 3524/4885 |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | SLC18A3 4614/4885TLR8 3481/4885TLR7 3524/4885 |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | SLC18A3 4614/4885TLR8 3481/4885TLR7 3524/4885 |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | SLC18A3 4614/4885TLR8 3481/4885TLR7 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.